Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

More than 5000 Australians struggling with rare and advanced cancers will be able to access two new immunotherapy drugs for ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

From today, thousands more Australians living with advanced and rare cancers will have access to affordable immunotherapy treatment options through ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

Ever-busy global pharmaceutical company Bristol Myers Squibb (NYSE: BMY) had quite an active February. Since much of the news ...

Its Oncology segment comprises around 27% of total revenues and 42% of its Innovative Medicine segment sales. Its oncology sales rose 20.9% on an operational basis in 2025, driven by strong market ...

Akeso (SEHK:9926) reported long term survival data from a Phase II study of cadonilimab in advanced cervical cancer, highlighting durable benefits in a setting with limited treatment options. The ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

In late February 2026, Bristol Myers Squibb and partner SystImmune reported that antibody-drug conjugate izalontamab brengitecan (iza-bren) achieved statistically significant, clinically meaningful ...